MEDTECH

European Union Approval for Tendyne Transcatheter Mitral Valve

February 3 2020
Jean Boulle Medtech Ltd. (the “Company”), founder  of Tendyne Holdings, Inc. ("Tendyne") and a Jean Boulle Group (the “Group”) company developing medical technologies that save lives [...]

Royal Brompton team completes five beating heart mitral valve repairs in three days

July 9 2019
A surgical team at Royal Brompton Hospital successfully completed five ‘beating heart’ mitral valve repair operations last week [...]

Jean Boulle Group $250 Million+ Abbott Laboratories acquisition of Tendyne Holdings Mitral Valve Company

September 8, 2015
JeanBoulle Medtech Ltd, a Jean Boulle Group (www.jeanboullegroup.com) medical technology company and founding investor of Tendyne Holdings, Inc. ("Tendyne"), is pleased to announce that Abbott Laboratories (NYSE: ABT) has closed its acquisition of Tendyne (www.tendyne.com). Abbott thereby acquires the remaining shares of Tendyne that it does not already own for US$250 million-plus potential future payments tied to regulatory milestones.  [...]

Jean Boulle Group announces first clinical US implant of Tendyne transcatheter mitral valve

May 1, 2015
Boulle Medtech, a Jean Boulle Group medical technology company and the founding investor of Tendyne Holdings, has announced that the Tendyne transcatheter mitral valve implant was successfully implanted in the first patient in the USA. This follows successful implants in Great Britain and Australia in December 2014. [...]

Jean Boulle Group announces first US clinical trial

April 24, 2015
Boulle Medtech Ltd, a Jean Boulle Group medical technology company and the founding investor of Tendyne Holdings, Inc. ("Tendyne"), is pleased to announce [...]

Jean Boulle Group reports successful first clinical trial implant of the Tendyne Transcatheter Mitral Valve

December 29, 2014
Boulle Medtech Ltd, a Jean Boulle Group company focusing on medical technology and a founding investor of Tendyne Holdings, Inc. ("Tendyne"), is pleased to announce that the Tendyne Transcatheter Mitral Valve Implant (TMVI) was successfully placed in the first patient enrolled in a three-continent, multicenter trial being conducted as part of the Tendyne Feasibility Study. The study is to generate insight into the safety and performance of the Tendyne device in inoperable patients suffering from mitral regurgitation. [...]

HEAD OFFICE
25B Boulevard Royal
L2449 Luxembourg
Grand Duchy Luxembourg

CALL US
Tel: +352 222 512
Fax: +352 222 413

The Jean Boulle Group acquires promising assets and projects, then optimizes their structure, management and development with private and public investment.

Copyright © 2019 Jean Boulle Group. All rights reserved.